Table 1.

Characteristics of the studies included

References	Year of publication	RCT phase	Region	Background therapy	Intervention			Comparator		Follow-up (weeks)
					Name	Dosage/ Frequency	Sample size (N)	Name	Sample size (N)
Nakagawa et al. 2020 [4]	2020	III	Japan	None	Delgocitinib	0.5%, b.i.d	106	Vehicle ointment	52	4
Papp et al. 2021 [5] (TRuE-AD1)	2021	III	Global	None	Ruxolitinib	0.75%, b.i.d	300	Vehicle ointment	126	8
						1.5%, b.i.d	300
Papp et al. 2021 [5] (TRuE-AD2)	2021	III	Global	None	Ruxolitinib	0.75%, b.i.d	298	Vehicle ointment	124	8
						1.5%, b.i.d	301
Nakagawa et al. 2021 [26]	2021	III	Japan	None	Delgocitinib	0.25%, b.i.d	69	Vehicle ointment	68	4
Nakagawa et al. 2019 [27]	2019	II	Japan	None	Delgocitinib	0.25%, b.i.d	34	Vehicle ointment	35	4
						0.5%, b.i.d	34
Nakagawa et al. 2018 [28]	2018	II	Japan	None	Delgocitinib	0.25%, b.i.d	69	Tacrolimus 0.1%, b.i.d Vehicle ointment	30	4
						0.5%, b.i.d	65
						1%, b.i.d	66
						3%, b.i.d	65		32
NCT03725722 [29]	2018	II	USA, Australia, Canada	None	Delgocitinib	0.1%, b.i.d	49	Vehicle ointment	50	10
						0.3%, b.i.d	50
						0.8%, b.i.d	50
						2%, b.i.d	51
NCT03683719 [30]	2018	II	USA, Denmark, Germany	None	Delgocitinib	0.1%, b.i.d	52	Vehicle ointment	50	18
						0.3%, b.i.d	51
						0.8%, b.i.d	52
						2%, b.i.d	53
Kim et al. 2020 [31]	2020	II	USA, Canada	Topical (nonmedicated emollients), 2.5% hydrocortisone cream	Ruxolitinib	0.15%, q.d	51	Triamcinolone acetonide (TAC) 0.1%, b.i.d Vehicle ointment	51	8
						0.5%, q.d	51
						1.5%, q.d	51
						1.5%, b.i.d	50		52
Bissonnette et al. 2016 [32]	2016	II	Canada	Topical (nonmedicated emollients)	Tofacitinib	2%, b.i.d		Vehicle ointment	34	4

RCT, randomized clinical trial; b.i.d., twice daily; q.d., once daily; USA, United States of America